As the first publication in the field of genetic engineering and biotechnology and a key driver in the explosion of the industry, GEN has paved the way for the development of new technologies and applications, investment and funding growth, and career opportunities. For more than 45 years, GEN has maintained unparalleled integrity, influence, and expertise and plays a pivotal role in reporting on and driving the productivity and growth of the industry. Exclusive features, reporting, and analysis enable new scientific discoveries, accelerate the pace of research, and drive large-scale funding and investments. GEN’s readers are empowered to translate research into real-world applications and to understand the impact of the developments driving the future of biotechnology. Key pillars of GEN’s editorial coverage include: · AI/Data · Bioprocessing · Cancer research · Drug discovery · Gene editing · Infectious Disease · Omics · Translational medicine In addition to the monthly magazine, GEN offers a wide array of multimedia content, including newsletters, webinars, virtual summits, podcasts, and sponsored content. In 2022, GEN hosted its first virtual summit ‘The State of Biotech’.
